Omnicell, Inc. provides automation and business analytics software solutions for medication and supply management in healthcare worldwide. The company operates through two segments, Automation and Analytics, and Medication Adherence. It offers Omnicell Automated Dispensing Cabinets, a dispensing system, which automates the management and dispensing of medications; SinglePointe, a software product that controls medications; AnywhereRN, a software which remotely queue medications from automated dispensing cabinets; Omnicell Analytics and Pandora Analytics reporting and data analytics tools; and Anesthesia Workstation that manages anesthesia supplies and medications. The company also provides XR2 Central Pharmacy System, a hospital pharmacy robotics system; Central and Satellite Pharmacy Manager, an automated pharmacy storage and retrieval system; Controlled Substance Management, a controlled substance inventory management system; OmniLinkRx, a prescription routing system; and WorkflowRx, an automated pharmacy storage, retrieval, and packaging system. In addition, it offers Omnicell Supply Management System, an automated dispensing system; Omnicell Tissue Center, which manages the chain of custody for bone and tissue specimens; OptiFlex MS that manages medical and surgical supplies; OptiFlex SS, a module for the perioperative areas; and OptiFlex CL, a module for the cardiac catheterization lab and other procedure areas. Further, the company provides IV Solutions; enterprise analytics and solutions; Omnicell Interface Software; Mach4 Pharma Systems Medimat, a robotic dispensing system; Omnicell SupplyX subscription software; RFID solutions; and consumable medication blister cards, packaging equipment, and ancillary products and services to institutional pharmacies. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was founded in 1992 and is headquartered in Mountain View, California.
Industry, Sector and Symbol
Industry Electronic computers
Sub-IndustryHealth Care Technology
SectorMedical
Phone650-251-6100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$787.31 million
Profitability
Miscellaneous
Employees2,350
Next Earnings Date4/25/2019 (Estimated)
OptionableOptionable
Omnicell (NASDAQ:OMCL) Frequently Asked Questions
What is Omnicell's stock symbol?
Omnicell trades on the NASDAQ under the ticker symbol "OMCL."
How were Omnicell's earnings last quarter?
Omnicell, Inc. (NASDAQ:OMCL) posted its quarterly earnings data on Thursday, February, 7th. The company reported $0.70 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.54 by $0.16. The firm had revenue of $211.75 million for the quarter, compared to analysts' expectations of $215.41 million. Omnicell had a return on equity of 9.31% and a net margin of 4.79%. The business's quarterly revenue was up 7.8% on a year-over-year basis. During the same period in the previous year, the firm earned $0.55 EPS. View Omnicell's Earnings History.
When is Omnicell's next earnings date?
What guidance has Omnicell issued on next quarter's earnings?
Omnicell updated its FY19 earnings guidance on Thursday, February, 7th. The company provided earnings per share (EPS) guidance of $2.40 to $2.60 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.41. Omnicell also updated its Q1 guidance to $0.38 to $0.43 EPS.
What price target have analysts set for OMCL?
6 analysts have issued 1-year price objectives for Omnicell's stock. Their predictions range from $61.00 to $86.00. On average, they expect Omnicell's stock price to reach $76.00 in the next year. This suggests that the stock has a possible downside of 10.8%. View Analyst Price Targets for Omnicell.
What is the consensus analysts' recommendation for Omnicell?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Omnicell in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Omnicell.
What are Wall Street analysts saying about Omnicell stock?
Here are some recent quotes from research analysts about Omnicell stock:
- 1. According to Zacks Investment Research, "Omnicell’s fourth-quarter 2018 performance was mixed. While earnings exceeded the Zacks Consensus Estimate, revenues fell short of the same. However, increasing operating expenses are a concern for Omnicell. A resilient hospital capital expenditure environment might affect the adoption of the company’s solutions. A tough competitive landscape is a dampener as well. Meanwhile, the company continued to see solid uptake of Omnicell XT. It also inked various deals for both the XR2 and the IVX Workflow products. A rise in bookings and product backlogs was also observed in the reported quarter. We are encouraged to note that the company is working on product innovation through R&D. Also, Omnicell is expected to gain traction from launches, strategic partnerships and digital transformation. Over the past three months, the company has outperformed its industry." (2/15/2019)
- 2. Cantor Fitzgerald analysts commented, ". We continue to rate OMCL shares at Overweight but increase our 12-month price target to $80 from $70. We recently attended the mid- year meeting of the Pharmacists (ASHP). ASHP is the company’s most important trade show. During the show, the company hosted a small analyst event and highlighted its newest product offerings. Specifically, it appears as though the company is making good progress with its XR2 and IVX automation products. However, the key focus appears to be on software and data analytics, in order to create work flow efficiencies for hospitals and pharmacies." (12/6/2018)
Has Omnicell been receiving favorable news coverage?
News headlines about OMCL stock have been trending somewhat positive on Thursday, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Omnicell earned a news sentiment score of 1.7 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 5.0 out of 10, meaning that recent news coverage is somewhat likely to have an effect on the stock's share price in the near future.
Who are some of Omnicell's key competitors?
What other stocks do shareholders of Omnicell own?
Who are Omnicell's key executives?
Omnicell's management team includes the folowing people:
- Mr. Randall A. Lipps, Founder, Exec. Chairman, Pres & CEO (Age 62)
- Mr. Peter J. Kuipers, Exec. VP & CFO (Age 47)
- Mr. Daniel S. Johnston, Exec. VP, Chief Legal & Admin. Officer and Corp. Sec. (Age 55)
- Mr. Robin G. Seim, Pres of Global Automation & Medication Adherence (Age 59)
- Mr. Joseph Brian Spears, VP of Corp. Fin. & Chief Accounting Officer (Age 59)
Who are Omnicell's major shareholders?
Omnicell's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (14.91%), Conestoga Capital Advisors LLC (3.86%), Dimensional Fund Advisors LP (3.41%), Eagle Asset Management Inc. (2.38%), Bank of New York Mellon Corp (2.36%) and Northern Trust Corp (1.36%). Company insiders that own Omnicell stock include Dan S Johnston, Gary S Petersmeyer, J Christopher Drew, James T Judson, Jorge R Taborga, Nhat H Ngo, Peter J Kuipers, Randall A Lipps, Robin Gene Seim and Sara J White. View Institutional Ownership Trends for Omnicell.
Which institutional investors are selling Omnicell stock?
OMCL stock was sold by a variety of institutional investors in the last quarter, including Conestoga Capital Advisors LLC, WINTON GROUP Ltd, Thrivent Financial for Lutherans, Elk Creek Partners LLC, Dimensional Fund Advisors LP, Falcon Point Capital LLC, Copper Rock Capital Partners LLC and Kornitzer Capital Management Inc. KS. Company insiders that have sold Omnicell company stock in the last year include Dan S Johnston, Gary S Petersmeyer, James T Judson, Jorge R Taborga, Nhat H Ngo, Peter J Kuipers, Randall A Lipps and Robin Gene Seim. View Insider Buying and Selling for Omnicell.
Which institutional investors are buying Omnicell stock?
OMCL stock was bought by a variety of institutional investors in the last quarter, including Stifel Financial Corp, Amundi Pioneer Asset Management Inc., Millennium Management LLC, Lisanti Capital Growth LLC, Geode Capital Management LLC, Tygh Capital Management Inc., Prudential Financial Inc. and Sawgrass Asset Management LLC. View Insider Buying and Selling for Omnicell.
How do I buy shares of Omnicell?
Shares of OMCL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Omnicell's stock price today?
One share of OMCL stock can currently be purchased for approximately $85.17.
How big of a company is Omnicell?
Omnicell has a market capitalization of $3.37 billion and generates $787.31 million in revenue each year. The company earns $37.72 million in net income (profit) each year or $1.53 on an earnings per share basis. Omnicell employs 2,350 workers across the globe.
What is Omnicell's official website?
How can I contact Omnicell?
Omnicell's mailing address is 590 EAST MIDDLEFIELD ROAD, MOUNTAIN VIEW CA, 94043. The company can be reached via phone at 650-251-6100 or via email at [email protected]
MarketBeat Community Rating for Omnicell (NASDAQ OMCL)
MarketBeat's community ratings are surveys of what our community members think about Omnicell and other stocks. Vote "Outperform" if you believe OMCL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OMCL will underperform the S&P 500 over the long term. You may vote once every thirty days.
